X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Wall Street Cautiously Optimistic After Gene Therapy Deals

    RoboCap: A Robotic Capsule to Improve Gut Drug Delivery

    Once More, M&As In Biotechechnology Industry Are Thriving

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Wall Street Cautiously Optimistic After Gene Therapy Deals

    RoboCap: A Robotic Capsule to Improve Gut Drug Delivery

    Once More, M&As In Biotechechnology Industry Are Thriving

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Middle East and South Asia

SEQENS Makes Multi-Million-Dollar Investment in U.S. R&D Laboratory

Content Team by Content Team
22nd March 2022
in Middle East and South Asia, News, Research & Development
SEQENS Makes Multi-Million-Dollar Investment in U.S. R&D Laboratory

SEQENS, an integrated leader in the manufacturing of active ingredients and pharmaceutical intermediates, announced a multi-million-dollar investment in its research and development laboratory located in Devens, Mass. The improvements will ensure that the new facility will operate at the highest standards of safety and quality, while also increasing SEQENS R&D capability and productivity in the US strengthening its global R&D network. The new facility will enhance Seqens capabilities in the development and production of active pharmaceutical ingredients (APIs) and active delivery systems (Lipids and Polymers) development. Completion of the project is expected beginning 2023.

The investment in Devens strengthens the company’s U.S. operations—which also includes a sales office and contract development and manufacturing operation in nearby Newburyport, Mass.—and signals SEQENS’ commitment to broadening its reach in the U.S. market. The investment comes just three months after SK Capital became a majority holder in SEQENS by merging it with its portfolio company Wavelength Pharmaceuticals to create one of the largest, most diversified contract development and manufacturing organizations (CDMOs) in the world.

New investors in SEQENS, alongside SK Capital, include Bpifrance and Nov Santé, with existing shareholders Mérieux Equity Partners, Ardian, and Eximium.

“With the support of our shareholders and with the combination of Wavelength’s technologies, products, and recognized know-how, we will accelerate the projects launched in recent months and further strengthen our positions to support our customers worldwide in the development of their projects“, said Pierre Luzeau, President of SEQENS.

The addition of Wavelength broadens SEQENS’ global reach by providing production facilities in Israel and India and sales offices in Europe and the U.S. It also broadens SEQENS’ API portfolio and its cytotoxic, steroidal, and high-potency products, along with Wavelength’s expertise in complex pharmaceutical synthesis are complementary to SEQENS core competencies. In total, the expanded portfolio now includes 200 active pharmaceutical ingredients, 500 pharmaceutical intermediates, as well as key specialty ingredients and chemicals.

In addition to the re-development of its Devens lab, SEQENS is investing significantly across the enterprise to support customers’ growth in both its commercial and development products and technology platforms, including custom polymers, lipids, flow chemistry, high potency APIs, and biocatalysts. The company is also committed to the highest levels of environmental, social and governance standards, with 15 EcoVadis platinum and gold sites among its global integrated network, which comprises 24 manufacturing sites, 10 R&D centers, more than 300 scientists and 3,200 employees located on 3 continents.

Previous Post

Germany Signs Vaccine Deals To Prepare For Future Outbreaks

Next Post

JSR Life Sciences Amsphere A3 Integrated into the Commercial Manufacturing of FDA-Approved Antibody Therapy

Related Posts

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies
Clinical Trials

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

7th November 2022
Facilities & Operation

CPhI Pharma Index Shows Unprecedented Global Pharma Optimism

5th November 2022
$2 Million Gene Therapy Might Become The Standard In The US
Drug Development

$2 Million Gene Therapy Might Become The Standard In The US

5th November 2022
News

Cancer Medicine Prices Jump 53% In Five Years In The U.S

3rd November 2022
FDA Approvals

Food And Drug Administration User Fee Has Been Reauthorized

3rd November 2022
Clinical Trials

Cancer Clinical Trials Get A Brand New Platform In Melbourne

3rd November 2022
Next Post
JSR Life Sciences Amsphere A3 Integrated into the Commercial Manufacturing of FDA-Approved Antibody Therapy

JSR Life Sciences Amsphere A3 Integrated into the Commercial Manufacturing of FDA-Approved Antibody Therapy

Latest News

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies
Clinical Trials

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

7th November 2022
Facilities & Operation

CPhI Pharma Index Shows Unprecedented Global Pharma Optimism

5th November 2022
$2 Million Gene Therapy Might Become The Standard In The US
Drug Development

$2 Million Gene Therapy Might Become The Standard In The US

5th November 2022
News

Cancer Medicine Prices Jump 53% In Five Years In The U.S

3rd November 2022
FDA Approvals

Food And Drug Administration User Fee Has Been Reauthorized

3rd November 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In